Terms: = Liver cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
259 results:
1. Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α.
Zhao R; Cheng S; Bai X; Zhang D; Fang H; Che W; Zhang W; Zhou Y; Duan W; Liang Q; Xiao L; Nie G; Hou Y
Biotechnol J; 2024 Apr; 19(4):e2400050. PubMed ID: 38651271
[TBL] [Abstract] [Full Text] [Related]
2. Exosomal lncRNA HEIH, an essential communicator for hepatocellular carcinoma cells and macrophage M2 polarization through the miR-98-5p/STAT3 axis.
Ai JH; Wen YZ; Dai SJ; Zhang LD; Huang ZJ; Shi J
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23686. PubMed ID: 38549433
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract] [Full Text] [Related]
4. MicroRNA let-7c-5p Alleviates in Hepatocellular Carcinoma by Targeting Enhancer of Zeste Homolog 2: A Study Intersecting Bioinformatic Analysis and Validated Experiments.
Lin T; Guo X; Du Q; Liu W; Zhong X; Wang S; Cao L
Crit Rev Immunol; 2024; 44(4):23-39. PubMed ID: 38505919
[TBL] [Abstract] [Full Text] [Related]
5. Role of UPF1 in lncRNA-HEIH regulation for hepatocellular carcinoma therapy.
Cha H; Kim M; Ahn N; Jeong SD; Ignatova E; Chi SW; Kim HH; Hwang J
Exp Mol Med; 2024 Feb; 56(2):344-354. PubMed ID: 38297160
[TBL] [Abstract] [Full Text] [Related]
6. HOMER3 promotes liver hepatocellular carcinoma cancer progression by -upregulating ezh2 and mediating miR-361/GPNMB axis.
Chen L; Shan X; Wan X; Zha W; Fan R
Pathol Res Pract; 2024 Feb; 254():155150. PubMed ID: 38266459
[TBL] [Abstract] [Full Text] [Related]
7. Decoding the multifaceted interventions between human sirtuin 2 and dynamic hepatitis B viral proteins to confirm their roles in HBV replication.
Piracha ZZ; Saeed U; Piracha IE; Noor S; Noor E
Front Cell Infect Microbiol; 2023; 13():1234903. PubMed ID: 38239506
[TBL] [Abstract] [Full Text] [Related]
8. ezh2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
9. ezh2 is a key component of hepatoblastoma tumor cell growth.
Glaser K; Schepers EJ; Zwolshen HM; Lake CM; Timchenko NA; Karns RA; Cairo S; Geller JI; Tiao GM; Bondoc AJ
Pediatr Blood Cancer; 2024 Feb; 71(2):e30774. PubMed ID: 37990130
[TBL] [Abstract] [Full Text] [Related]
10. EMT-related gene risk model establishment for prognosis and drug treatment efficiency prediction in hepatocellular carcinoma.
Gao X; Yang C; Li H; Shao L; Wang M; Su R
Sci Rep; 2023 Nov; 13(1):20380. PubMed ID: 37990105
[TBL] [Abstract] [Full Text] [Related]
11. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract] [Full Text] [Related]
12. Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.
Amin MN; El-Far YM; El-Mowafy M; Elgaml A
Clin Epigenetics; 2023 Nov; 15(1):180. PubMed ID: 37941056
[TBL] [Abstract] [Full Text] [Related]
13. LncRNA CALML3-AS1 modulated by m
Zhang H; Wang SQ; Zhu JB; Wang LN; Lin H; Li LF; Cheng YD; Duan CJ; Zhang CF
Cancer Gene Ther; 2023 Dec; 30(12):1649-1662. PubMed ID: 37884580
[TBL] [Abstract] [Full Text] [Related]
14. lncRNA SNHG9 enhances liver cancer stem cell self-renewal and tumorigenicity by negatively regulating PTEN expression via recruiting ezh2.
Yang S; Ruan X; Hu B; Tu J; Cai H
Cell Tissue Res; 2023 Dec; 394(3):441-453. PubMed ID: 37851112
[TBL] [Abstract] [Full Text] [Related]
15. Targeting WNT/β-Catenin via Modulating ezh2 Function: A New Chapter in the Treatment of β-Catenin Mutant Hepatocellular Carcinoma?
Hung MH; Wang XW
Cancer Res; 2023 Nov; 83(21):3498-3500. PubMed ID: 37747420
[TBL] [Abstract] [Full Text] [Related]
16. β-CATENIN stabilizes HIF2 through lncRNA and inhibits intravenous immunoglobulin immunotherapy.
Nakagawa C; Kadlera Nagaraj M; Hernandez JC; Uthay Kumar DB; Shukla V; Machida R; Schüttrumpf J; Sher L; Farci P; Mishra L; Tahara SM; Ou JJ; Machida K
Front Immunol; 2023; 14():1204907. PubMed ID: 37744383
[TBL] [Abstract] [Full Text] [Related]
17. Analysis on ezh2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma.
Zhao H; Liu H; Kang W; Zhan C; Man Y; Qu T
BMC Med Genomics; 2023 Aug; 16(1):201. PubMed ID: 37626362
[TBL] [Abstract] [Full Text] [Related]
18. WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.
Rialdi A; Duffy M; Scopton AP; Fonseca F; Zhao JN; Schwarz M; Molina-Sanchez P; Mzoughi S; Arceci E; Abril-Fornaguera J; Meadows A; Ruiz de Galarreta M; Torre D; Reyes K; Lim YT; Rosemann F; Khan ZM; Mohammed K; Wang X; Yu X; Lakshmanan M; Rajarethinam R; Tan SY; Jin J; Villanueva A; Michailidis E; De Jong YP; Rice CM; Marazzi I; Hasson D; Llovet JM; Sobota RM; Lujambio A; Guccione E; Dar AC
Nat Cancer; 2023 Aug; 4(8):1157-1175. PubMed ID: 37537299
[TBL] [Abstract] [Full Text] [Related]
19. The Role of CDK20 Protein in Carcinogenesis.
Chivukula S; Malkhed V
Curr Drug Targets; 2023; 24(10):790-796. PubMed ID: 37469151
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of the Prognosis Prediction Ability of a Necroptosis-Related Gene Signature and its Relationship With the Hepatocellular Carcinoma Immune Microenvironment Using Bioinformatics Analysis and Experimental Validation.
Guan R; Mei J; Guo R
Technol Cancer Res Treat; 2023; 22():15330338231182208. PubMed ID: 37335078
[No Abstract] [Full Text] [Related]
[Next]
